Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
School of Public Health, University of Haifa, Haifa, Israel.
Liver Int. 2022 Nov;42(11):2377-2389. doi: 10.1111/liv.15404. Epub 2022 Sep 1.
Non-alcoholic fatty liver disease (NAFLD) affects at least 25% of the general population and is an increasingly important cause of cirrhosis and hepatocellular carcinoma. Although it is the research focus of the hepatology field, it is clear that primary care physicians are seeing the majority of NAFLD patients and are in a pivotal position to provide quality care. In this article, we review the role of primary care in the management of NAFLD. NAFLD is common in patients with diabetes, obesity and other metabolic risk factors. Abdominal ultrasonography is the most commonly used method to diagnose fatty liver. Simple fibrosis scores have high negative predictive values in excluding advanced liver fibrosis and future liver-related events and can be used in primary care as initial evaluation. An abnormal result should be followed by subsequent workup or specialist referral. Primary care is the ideal setting to institute multidisciplinary care, especially the involvement of dietitians and physical activity trainers in lifestyle intervention, as well as initiating the discussion of bariatric surgery in patients with severe obesity. Although specific drug treatment for steatohepatitis would require a more precise diagnosis, metabolic drugs that improve both steatohepatitis and cardiovascular outcomes (e.g. glucagon-like peptide-1 receptor agonists) may be considered in patients with NAFLD.
非酒精性脂肪性肝病(NAFLD)影响至少 25%的普通人群,是肝硬化和肝细胞癌的一个越来越重要的病因。尽管它是肝病学领域的研究重点,但显然初级保健医生正在接诊大多数 NAFLD 患者,并且处于提供优质护理的关键位置。在本文中,我们复习了初级保健在 NAFLD 管理中的作用。NAFLD 在患有糖尿病、肥胖症和其他代谢危险因素的患者中很常见。腹部超声检查是诊断脂肪肝最常用的方法。简单的纤维化评分在排除晚期肝纤维化和未来的肝脏相关事件方面具有很高的阴性预测值,可以在初级保健中作为初始评估使用。异常结果应随后进行进一步检查或专科转诊。初级保健是实施多学科护理的理想场所,特别是营养师和体力活动培训师参与生活方式干预,以及在严重肥胖患者中讨论减重手术。虽然对于脂肪性肝炎的特定药物治疗需要更精确的诊断,但对于同时改善脂肪性肝炎和心血管结局的代谢药物(例如胰高血糖素样肽-1 受体激动剂)可能会被考虑用于 NAFLD 患者。